Gastrointestinal Stromal Tumors Market Research Report- Forecast To 2027

Global Gastrointestinal Stromal Tumors Market Research Report: By Indication (Stomach, Small Intestine, Other Indication), Diagnosis (Endoscopic Ultrasound, Biopsy, Others), Treatment (Surgery, Targeted Therapy), and End-User– Global Forecast Till 2027

ID: MRFR/Pharma/1054-HCR | February 2021 | Region: Global | 80 Pages         

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Gastrointestinal Stromal Tumors Market, by Indication

6.1 Introduction

6.2 Stomach

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Small intestine

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 Large intestine (colon)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Gastrointestinal Stromal Tumors Market, by Diagnosis

7.1 Introduction

7.2 Imaging Studies

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Plain abdominal radiography

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Barium and air (double-contrast) series

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Return-flow enema

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Computed tomography scans of the abdomen and pelvis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Magnetic resonance imaging

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Endoscopy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Endoscopic ultrasonography

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Gastrointestinal Stromal Tumors Market, by Treatment

8.1 Introduction

8.2 Surgery

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Targeted therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3.1 Tyrosine kinase inhibitors (TKIs)

8.3.2 Imatinib

8.3.3 Sunitinib

8.3.4 Regorafenib

8.3.5 Others

8.4 Radiation therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5 Chemotherapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.6 Ablation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.6.1 Radiofrequency ablation (RFA)

8.6.2 Ethanol (alcohol) ablation

8.6.3 Microwave thermotherapy

8.6.4 Cryosurgery (cryotherapy)

8.6.5 Others

8.7 Embolization

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.8 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Gastrointestinal Stromal Tumors Market, by End-User

9.1 Introduction

9.2 Hospitals & clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3 Ambulatory surgical centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 10. Global Gastrointestinal Stromal Tumors Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K.

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 The Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12. Company Profiles

12.1 Bayer AG

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Novartis AG

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Immunicum AB

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 F. Hoffmann-La Roche Ltd.

12.4.1 Company Overview

12.4.2 Technology/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 AB SCIENCES

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Arog Pharmaceuticals, Inc.

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Boston Biomedical, Inc.

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Sun Pharmaceutical Industries Limited

12.8.1 Overview

12.8.2 Product/ Technology Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Pfizer Inc.

12.9.1 Overview

12.9.2 Product Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 NATCO Pharma Limited

12.10.1 Overview

12.10.2 Product Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Others

Chapter 17 Appendix


LIST OF TABLES

Table 1 Global Gastrointestinal Stromal Tumors Market Synopsis, 2020-2027

Table 2 Global Gastrointestinal Stromal Tumors Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Global Gastrointestinal Stromal Tumors Market, by Region, 2020-2027, (USD Million)

Table 4 Global Gastrointestinal Stromal Tumors Market, by Indication, 2020-2027, (USD Million)

Table 5 Global Gastrointestinal Stromal Tumors Market, by Diagnosis, 2020-2027, (USD Million)

Table 6 Global Gastrointestinal Stromal Tumors Market, by Treatment, 2020-2027, (USD Million)

Table 7 Global Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 8 North America Global Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 9 North America Global Gastrointestinal Stromal Tumors Market, by Diagnosis, 2020-2027, (USD Million)

Table 10 North America Global Gastrointestinal Stromal Tumors Market, by Treatment, 2020-2027, (USD Million)

Table 11 North America Global Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 12 U.S. Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 13 U.S. Gastrointestinal Stromal Tumors Market, by Diagnosis, 2020-2027, (USD Million)

Table 14 U.S. Gastrointestinal Stromal Tumors Market, by Treatment, 2020-2027, (USD Million)

Table 15 U.S. Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 16 Canada Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 17 Canada Gastrointestinal Stromal Tumors Market, by Diagnosis, 2020-2027, (USD Million)

Table 18 Canada Gastrointestinal Stromal Tumors Market, by Treatment, 2020-2027, (USD Million)

Table 19 Canada Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 20 Canada Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 21 South America Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 22 South America Gastrointestinal Stromal Tumors Market, by Diagnosis, 2020-2027, (USD Million)

Table 23 South America Gastrointestinal Stromal Tumors Market, by Treatment, 2020-2027, (USD Million)

Table 24 South America Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 25 Europe Gastrointestinal Stromal Tumors Market, by Indication, 2020-2027, (USD Million)

Table 26 Europe Gastrointestinal Stromal Tumors Market, by Diagnosis, 2020-2027, (USD Million)

Table 27 Europe Gastrointestinal Stromal Tumors Market, by Treatment, 2020-2027, (USD Million)

Table 28 Europe Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 29 Western Europe Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 30 Western Europe Gastrointestinal Stromal Tumors Market, by Indication, 2020-2027, (USD Million)

Table 31 Western Europe Gastrointestinal Stromal Tumors Market, by Diagnosis, 2020-2027, (USD Million)

Table 32 Western Europe Gastrointestinal Stromal Tumors Market, by Treatment, 2020-2027, (USD Million)

Table 33 Western Europe Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 24 Eastern Europe Gastrointestinal Stromal Tumors Market, by Indication, 2020-2027, (USD Million)

Table 35 Eastern Europe Gastrointestinal Stromal Tumors Market, by Diagnosis, 2020-2027, (USD Million)

Table 36 Eastern Europe Gastrointestinal Stromal Tumors Market, by Treatment, 2020-2027, (USD Million)

Table 37 Eastern Europe Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 38 Asia Pacific Gastrointestinal Stromal Tumors Market, by Indication, 2020-2027, (USD Million)

Table 39 Asia Pacific Gastrointestinal Stromal Tumors Market, by Diagnosis, 2020-2027, (USD Million)

Table 40 Asia Pacific Gastrointestinal Stromal Tumors Market, by Treatment, 2020-2027, (USD Million)

Table 41 Asia Pacific Gastrointestinal Stromal Tumors Market, by End-User, 2020-2027, (USD Million)

Table 42 Middle East & Africa Gastrointestinal Stromal Tumors Market, by Indication, 2020-2027, (USD Million)

Table 43 Middle East & Africa Gastrointestinal Stromal Tumors Market, by Diagnosis, 2020-2027, (USD Million)

Table 44 Middle East & Africa Gastrointestinal Stromal Tumors Market, by Treatment 2020-2027, (USD Million)

Table 45 Middle East & Africa Gastrointestinal Stromal Tumors Market, by End-User 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Gastrointestinal Stromal Tumors Market

Figure 3 Segmentation Market Dynamics for Global Gastrointestinal Stromal Tumors Market

Figure 4 Global Gastrointestinal Stromal Tumors Market Share, by Indication 2020

Figure 5 Global Gastrointestinal Stromal Tumors Market Share, by Diagnosis 2020

Figure 6 Global Gastrointestinal Stromal Tumors Market Share, by Treatment 2020

Figure 7 Global Gastrointestinal Stromal Tumors Market Share, by End-User 2020

Figure 8 Global Gastrointestinal Stromal Tumors Market Share, by Region, 2020

Figure 9 North America Gastrointestinal Stromal Tumors Market Share, by Country, 2020

Figure 10 Europe Gastrointestinal Stromal Tumors Market Share, by Country, 2020

Figure 11 Asia Pacific Gastrointestinal Stromal Tumors Market Share, by Country, 2020

Figure 12 Middle East & Africa Gastrointestinal Stromal Tumors Market Share, by Country, 2020

Figure 13 Global Gastrointestinal Stromal Tumors Market: Company Share Analysis, 2020 (%)

Figure 14 Bayer AG: Key Financials

Figure 15 Bayer AG: Segmental Revenue

Figure 16 Bayer AG: Geographical Revenue

Figure 17 Novartis AG: Key Financials

Figure 18 Novartis AG: Segmental Revenue

Figure 19 Novartis AG: Geographical Revenue

Figure 20 Immunicum AB: Key Financials

Figure 21 Immunicum AB: Segmental Revenue

Figure 22 Immunicum AB: Geographical Revenue

Figure 23 F. Hoffmann-La Roche Ltd.: Key Financials

Figure 24 F. Hoffmann-La Roche Ltd.: Segmental Revenue

Figure 25 F. Hoffmann-La Roche Ltd.: Geographical Revenue

Figure 26 AB SCIENCES: Key Financials

Figure 27 AB SCIENCES: Segmental Revenue

Figure 28 AB SCIENCES. Geographical Revenue

Figure 29 Arog Pharmaceuticals, Inc.: Key Financials

Figure 30 Arog Pharmaceuticals, Inc.: Segmental Revenue

Figure 31 Arog Pharmaceuticals, Inc.: Geographical Revenue

Figure 32 F. Hoffman- La Roche: Key Financials

Figure 33 F. Hoffman- La Roche: Segmental Revenue

Figure 34 F. Hoffman- La Roche: Geographical Revenue

Figure 35 Cascade Healthcare Products, Inc: Key Financials

Figure 36 Cascade Healthcare Products, Inc: Segmental Revenue

Figure 37 Cascade Healthcare Products, Inc: Geographical Revenue

Figure 38 Pfizer Inc.: Key Financials

Figure 39 Pfizer Inc.: Segmental Revenue

Figure 40 Pfizer Inc.: Geographical Revenue

Figure 41 NATCO Pharma Limited: Key Financials

Figure 42 NATCO Pharma Limited: Segmental Revenue

Figure 43 NATCO Pharma Limited: Geographical Revenue

Figure 44 Flexicare Medical Limited: Key Financials

Figure 45 Flexicare Medical Limited Segmental Revenue

Figure 46 Flexicare Medical Limited: Geographical Revenue

Figure 47 Farla medical Ltd.: Key Financials

Figure 48 Farla medical Ltd.: Segmental Revenue

Figure 49 Farla medical Ltd.: Geographical Revenue

Figure 50 Jiangsu Delfu Co. Ltd: Key Financials

Figure 51 Jiangsu Delfu Co. Ltd: Segmental Revenue

Figure 52 Jiangsu Delfu Co. Ltd: Geographical Revenue

Figure 53 Biocon Ltd: Key Financials

Figure 54 Biocon Ltd: Segmental Revenue

Figure 55 Biocon Ltd: Geographical Revenue

Gastrointestinal Stromal Tumors Market Speak to Analyst Request a Free Sample

Gastrointestinal Stromal Tumors Market Overview


The Gastrointestinal Stromal Tumors Market is evaluated to grow at a CAGR of 7%. In the upcoming years, of the forecast period of 2021-2028, the market value will further increase up to USD 1.7 Billion. The gastrointestinal stromal tumor is a tumor that appears in the gastrointestinal tract. These tumors originate from the specialized cells called Interstitial Cells of Cajal (ICC).


Thus, Gastrointestinal Stromal Tumors are a form of cancer known as soft tissue sarcoma. The tissue sarcoma further develops in the connective and supportive tissues. With significant technological advancements, the Gastrointestinal Stromal Tumors Global Market is projected to have substantial growth in the future.


COVID-19 Analysis


The COVID-19 disease led to a massive economic disruption across the world. The healthcare system was highly affected due to the spread. The treatment of other diseases was halted for a significant period. Along with that, the lockdown heavily impacted the supply chain of the Gastrointestinal Stromal Tumors Market. However, it is anticipated that with the lessening spread of coronavirus disease, the market will regain its growth in the future.


Market Dynamics


Market Drivers


The rising cases of gastrointestinal diseases and other cancerous diseases are the crucial drivers of the Gastrointestinal Stromal Tumors Market. Also, the increasing funds for development and research in life sciences will further enhance the market growth.


Restraints


The availability of fake and misbranded drugs is considered a significant restraint. As a result, it can create confusion and hinder the Gastrointestinal Stromal Tumors Market Value.


Opportunities


The increasing population of the older generation and rapid technological advancements is evaluated to provide various opportunities for market growth.


Challenges


The low awareness for the treatment of chronic diseases and the low availability of skilled medical experts in various low and middle-income countries is a major challenge. Also, the demand for the non-invasive procedure is a significant challenge for the Gastrointestinal Stromal Tumors Market Growth.


Cumulative Analysis


The Compound Annual Growth Rate (CAGR) of the Gastrointestinal Stromal Tumors Market is estimated to reach up to 7%. According to the Gastrointestinal Stromal Tumors Market Analysis by MRFR, the value is projected to reach up to USD 1.7 Billion by the studied forecast period of 2021-2028.


Value Chain Analysis


The rising demands and technological development will lead to raising the Gastrointestinal Stromal Tumors Market Trends. Also, investments for development and research by key players and initiatives by governments will simultaneously improve the value chain of the market.


Market Segmentations


The Gastrointestinal Stromal Tumors Market Size is divided into treatment, indication, end-user, and diagnosis. Based upon treatment, the market is divided into Radiation Therapy, Embolization, Surgery, Targeted Therapy, Ablation, Chemotherapy, and Others. Further, the targeted therapy is segmented into Regorafenic, Imatinib, Sunitinib, Tyrosine Kinase Inhibitors, and Others. Along with that, ablation is divided into Microwave Thermotherapy, Ethanol, Radiofrequency Ablation, Cryosurgery, and Others.


Based upon indication, the Gastrointestinal Stromal Tumors Market is divided into Large Intestine, Small Intestine, Stomach, and Others.


The end-user segment of the Gastrointestinal Stromal Tumors Market is divided into Ambulatory Surgical Centres, Clinics and Hospitals, and Others.


Lastly, the diagnosis segment is divided into Endoscopy, Tomography Scans of Pelvis and Abdomen, Plain Abdominal Radiography, Imaging Studies, Endoscopic Ultrasonography, Air and Barium (Double Contrast), series, Magnetic Resonance Imaging, and Others.


Regional Analysis


Geographically, the Gastrointestinal Stromal Tumors industry is divided into Asia-pacific, Europe, Africa, and the Middle East, and the Americas. Gastrointestinal Stromal Tumors Global Market Analysis suggests that Americas will hold the largest share in the studied forecast period. The Americas region is divided into Latin and North America. The increasing cases of genetic disorders in countries such as Canada and the USA are vital reasons for growth. Also, the easy availability of advanced healthcare facilities for patients is propelling the market growth.


Secondly, Europe will hold the second-largest Gastrointestinal Stromal Tumors Market Share. This region consists of countries such as Italy, France, Germany, the UK, Spain, and others.  The rising cases f stromal tumors in these counties are majorly driving the market.


Thirdly, Asia-Pacific is evaluated to observe the fastest CAGR during the studied forecast period. Rapid development in healthcare facilities and rising awareness for the treatment of chronic diseases are boosting the market growth. Also, rising development and research in major countries such as China, India, and Japan are crucial for the significant Gastrointestinal Stromal Tumors Market Growth.


Africa and the Middle East are evaluated to observe the steady growth. Due to the limited availability of resources and healthcare facilities and low awareness for chronic diseases the region is evaluated to have the least share.  


Competitive Landscape


The Gastrointestinal Stromal Tumors Market is fragmented with the presence of several key players. These key players play a crucial role in enhancing market growth. They take important strategic steps such as mergers, partnerships, collaborations, etc. Some of the key players of the market are as follows.



  • Immunicum AB (Sweden)

  • NATCO Pharma Limited (US)

  • AB Science (France)

  • Bayer AG (Germany)

  • Arog Pharmaceuticals, Inc (US)

  • Sun Pharmaceutical Industries Limited India)

  • Novartis AG (Switzerland)

  • Hoffman-La Roche Ltd. (Switzerland)

  • Pfizer Inc. (US)

  • Boston Biomedical, Inc. (US)


Recent Developments


No Recent Developments Were Found.


Report Overview


The overview of the Gastrointestinal Stromal Tumors Market Outlook is listed below.



  • Market Overview

  • COVID-19 Analysis

  • Dynamics of the Market

  • Value Chain Analysis

  • Market Segmentation

  • Regional Analysis

  • Competitive Analysis

  • Recent Development


Report Score and Segmentation


The report score gives valuable insight into the Gastrointestinal Stromal Tumors Market Analysis. It highlights information about the market dynamics such as challenges, opportunities, key players and their strategies, etc. The information provided in this report is collected from primary and secondary sources.


Segmentation



  • By Treatment

  • Radiation Therapy

  • Embolization, Surgery

  • Targeted Therapy

  • Regorafenib

  • Imatinib

  • Sunitinib

  • Tyrosine Kinase Inhibitors

  • Others

  • Ablation

  • Microwave Thermotherapy

  • Ethanol

  • Radiofrequency Ablation

  • Cryosurgery

  • Others

  • Chemotherapy

  • Others


 



  • By Indication

  • Large Intestine

  • Small Intestine

  • Stomach

  • Others


 



  • By Diagnosis

  • Endoscopy

  • Tomography Scans of Pelvis and Abdomen

  • Plain Abdominal Radiography

  • Imaging Studies

  • Endoscopic

  • Ultrasonography

  • Air and Barium (Double Contrast) Series

  • Magnetic Resonance Imaging

  • Others


 



  • By End-User

  • Ambulatory Surgical Centres

  • Clinics and Hospitals

  • Others


 



  • By Region

  • Europe

  • Africa and the Middle East

  • Asia-Pacific

  • Americas


 



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The outlook of the global gastrointestinal stromal tumors market looks very promising.

global gastrointestinal stromal tumors market is projected to grow at approximately 7% CAGR during the assessment period (2018-2023).

Investments and funding in the field of life science research and favorable reimbursements policies and health insurance are the major tailwinds pushing the growth of the global gastrointestinal stromal tumors market.

North America holds the largest share in the global gastrointestinal stromal tumors market, followed by Europe and the Asia Pacific, respectively.

Novartis AG (Switzerland), Bayer AG (Germany), Immunicum AB (Sweden), AB SCIENCES (FRANCE), F. Hoffmann-La Roche Ltd.(Switzerland), Arog Pharmaceuticals, Inc. (US), Sun Pharmaceutical Industries Limited (India), Boston Biomedical, Inc. (US), Pfizer Inc. (US), and NATCO Pharma Limited (US), are some of the major players operating in the gastrointestinal stromal tumors market.